Induced Pluripotent Stem Cell-derived Engineered Human Myocardium Cell（Repairon GmbH）

N/A

Report date: 2024/04/01 14:39:20

Base Information

Drug NameInduced Pluripotent Stem Cell-derived Engineered Human Myocardium Cell（Repairon GmbH）
Drug Alias NameCardiomyocyte implantation via engineered heart muscle (EHM)（Repairon）BioVAT-HF
ClassificationCell and gene therapy > Cell therapy > Somatic cell > Myocardium therapyCell and gene therapy > Cell therapy > Source of cells > iPSC-derived
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsHeart Failure
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Medical Center GottingenDeutsches Zentrum Für Herz-Kreislauf-Forschung (Dzhk)University Medical Center Freiburg +[4] 
China Registration ClassN/A

Develop Information

Active CompaniesDeutsches Zentrum Für Herz-Kreislauf-Forschung (Dzhk)University Medical Center GoettingenRepairon GmbH +[4] 
Inactive CompaniesN/A
Active IndicationsHeart Failure
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A